Course
Genomic Sequencing Technologies
BIOL-40237
Review current genomic sequencing technologies while exploring the scientific and medical applications that these technologies are enabling. We will cover traditional and modern sequencing platforms, new technologies for dissecting genetics and epigenetics information, genetic test design strategies, and medicine. For each topic, we start with theoretical considerations and explore current literature examples. Understanding current and developing next-generation sequencing technologies is the primary goal. Discussion of genetic applications enabled by emerging technologies is touched upon.
While not mandatory, the instructor suggests taking Genetics or Cell and Molecular Biology as a prerequisite for enrolling in this course.
Course Information
Online
3.00 units
$725.00
Course sessions
Add To Cart
Add To Cart
Instructor:
Li Weng is a seasoned R&D leader with 20 years of research experience in genomic science. Over the years, Dr. Weng has built up broad and in-depth knowledge of different technology platforms, including sequencing and microarray. She currently serves as SVP, Head of R&D at AccuraGen, leading the innovation of next generation sequencing (NGS) based liquid biopsy tests for personalized medicine. Before AccuraGen, Dr. Weng was the Associate Director of R&D at Adaptive Biotechnologies/Sequenta where she spearheaded the development of clonoSEQ, the first NGS based Minimal Residual Disease (MRD) test that received FDA clearance for hematological malignancies. Prior to Adaptive Biotechnologies/Sequenta, Dr. Weng served as an R&D scientist at Affymetrix where she played a major role in the development of multiple high throughput whole genome genotyping and copy number variant (CNV) detection products.
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.
Li Weng is a seasoned R&D leader with 20 years of research experience in genomic science. Over the years, Dr. Weng has built up broad and in-depth knowledge of different technology platforms, including sequencing and microarray. She currently serves as SVP, Head of R&D at AccuraGen, leading the innovation of next generation sequencing (NGS) based liquid biopsy tests for personalized medicine. Before AccuraGen, Dr. Weng was the Associate Director of R&D at Adaptive Biotechnologies/Sequenta where she spearheaded the development of clonoSEQ, the first NGS based Minimal Residual Disease (MRD) test that received FDA clearance for hematological malignancies. Prior to Adaptive Biotechnologies/Sequenta, Dr. Weng served as an R&D scientist at Affymetrix where she played a major role in the development of multiple high throughput whole genome genotyping and copy number variant (CNV) detection products.
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.
Full Bio
Section ID:
184086
Class type:
Online Asynchronous.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
No textbook required.
Policies:
- No refunds after: 1/13/2025
Schedule:
No information available at this time.
Instructor:
Li Weng
Li Weng
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.
Li Weng is a seasoned R&D leader with 20 years of research experience in genomic science. Over the years, Dr. Weng has built up broad and in-depth knowledge of different technology platforms, including sequencing and microarray. She currently serves as SVP, Head of R&D at AccuraGen, leading the innovation of next generation sequencing (NGS) based liquid biopsy tests for personalized medicine. Before AccuraGen, Dr. Weng was the Associate Director of R&D at Adaptive Biotechnologies/Sequenta where she spearheaded the development of clonoSEQ, the first NGS based Minimal Residual Disease (MRD) test that received FDA clearance for hematological malignancies. Prior to Adaptive Biotechnologies/Sequenta, Dr. Weng served as an R&D scientist at Affymetrix where she played a major role in the development of multiple high throughput whole genome genotyping and copy number variant (CNV) detection products.
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.
Add To Cart
Add To Cart
Instructor:
Li Weng is a seasoned R&D leader with 20 years of research experience in genomic science. Over the years, Dr. Weng has built up broad and in-depth knowledge of different technology platforms, including sequencing and microarray. She currently serves as SVP, Head of R&D at AccuraGen, leading the innovation of next generation sequencing (NGS) based liquid biopsy tests for personalized medicine. Before AccuraGen, Dr. Weng was the Associate Director of R&D at Adaptive Biotechnologies/Sequenta where she spearheaded the development of clonoSEQ, the first NGS based Minimal Residual Disease (MRD) test that received FDA clearance for hematological malignancies. Prior to Adaptive Biotechnologies/Sequenta, Dr. Weng served as an R&D scientist at Affymetrix where she played a major role in the development of multiple high throughput whole genome genotyping and copy number variant (CNV) detection products.
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.
Li Weng is a seasoned R&D leader with 20 years of research experience in genomic science. Over the years, Dr. Weng has built up broad and in-depth knowledge of different technology platforms, including sequencing and microarray. She currently serves as SVP, Head of R&D at AccuraGen, leading the innovation of next generation sequencing (NGS) based liquid biopsy tests for personalized medicine. Before AccuraGen, Dr. Weng was the Associate Director of R&D at Adaptive Biotechnologies/Sequenta where she spearheaded the development of clonoSEQ, the first NGS based Minimal Residual Disease (MRD) test that received FDA clearance for hematological malignancies. Prior to Adaptive Biotechnologies/Sequenta, Dr. Weng served as an R&D scientist at Affymetrix where she played a major role in the development of multiple high throughput whole genome genotyping and copy number variant (CNV) detection products.
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.
Full Bio
Section ID:
185575
Class type:
Online Asynchronous.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
All course materials are included unless otherwise stated.
Policies:
- No refunds after: 3/28/2025
Schedule:
No information available at this time.
Instructor:
Li Weng
Li Weng
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.
Li Weng is a seasoned R&D leader with 20 years of research experience in genomic science. Over the years, Dr. Weng has built up broad and in-depth knowledge of different technology platforms, including sequencing and microarray. She currently serves as SVP, Head of R&D at AccuraGen, leading the innovation of next generation sequencing (NGS) based liquid biopsy tests for personalized medicine. Before AccuraGen, Dr. Weng was the Associate Director of R&D at Adaptive Biotechnologies/Sequenta where she spearheaded the development of clonoSEQ, the first NGS based Minimal Residual Disease (MRD) test that received FDA clearance for hematological malignancies. Prior to Adaptive Biotechnologies/Sequenta, Dr. Weng served as an R&D scientist at Affymetrix where she played a major role in the development of multiple high throughput whole genome genotyping and copy number variant (CNV) detection products.
Dr. Weng earned her Ph.D degree in Cancer Biology from University of Chicago and received post-doc training at Lawrence Berkeley National Laboratory/Joint Genome Institute. She is passionate about applying genomic technologies to advance modern medicine and improve human health.
Related Courses
Classroom type:
Live Online
In-Person
Online
Hybrid
